News

Press Release: EMA grants orphan drug designation for PNH to Amyndas Pharmaceuticals’ novel complement inhibitor

August 27, 2014

“EMA grants orphan drug designation for PNH to Amyndas Pharmaceuticals’ novel complement inhibitor. Amyndas Pharmaceuticals SA, the complement therapeutics company, announced that the European Medicines Agency (EMA) has granted AMY-101, a potent complement C3 inhibitor, an Orphan Drug Designation for the treatment of Paroxysmal Nocturnal Hemoglobinuria.”

To read entire press release: www.prlog.org

 

Comments are closed.